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Abstract
Cancer cachexia is a wasting condition, driven by systemic inflammation and oxidative stress. This study investigated
eicosapentaenoic acid (EPA) in combination with oxypurinol as a treatment in a mouse model of cancer cachexia. Mice with
cancer cachexia were randomized into 4 treatment groups (EPA (0.4 g/kg/day), oxypurinol (1 mmol/L ad-lib), combination,
or control), and euthanized after 29 days. Analysis of oxidative damage to DNA, mRNA analysis of pro-oxidant, antioxidant
and proteolytic pathway components, along with enzyme activity of pro- and antioxidants were completed on
gastrocnemius muscle. The control group displayed earlier onset of tumor compared to EPA and oxypurinol groups
(P,0.001). The EPA group maintained body weight for an extended duration (20 days) compared to the oxypurinol (5 days)
and combination (8 days) groups (P,0.05). EPA (18.263.2 pg/ml) and combination (18.463.7 pg/ml) groups had
significantly higher 8-OH-dG levels than the control group (12.961.4 pg/ml, P#0.05) indicating increased oxidative damage
to DNA. mRNA levels of GPx1, MURF1 and MAFbx were higher following EPA treatment compared to control (P#0.05).
Whereas oxypurinol was associated with higher GPx1, MnSOD, CAT, XDH, MURF1, MAFbx and UbB mRNA compared to
control (P#0.05). Activity of total SOD was higher in the oxypurinol group (32.261.5 U/ml) compared to control
(27.061.3 U/ml, P,0.01), GPx activity was lower in the EPA group (8.7662.0 U/ml) compared to control (14.061.9 U/ml,
P,0.05), and catalase activity was lower in the combination group (14.462.8 U/ml) compared to control (20.962.0 U/ml,
P,0.01). There was no change in XO activity. The increased rate of weight decline in mice treated with oxypurinol indicates
that XO may play a protective role during the progression of cancer cachexia, and its inhibition is detrimental to outcomes.
In combination with EPA, there was little significant improvement from control, indicating oxypurinol is unlikely to be a
viable treatment compound in cancer cachexia.
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Introduction
Many forms of cancer present with a complex metabolic profile
characterized by loss of lean body mass and adipose tissue, known
as cancer cachexia. Approximately half of all cancer patients
develop cachexia [1], with the prevalence rising as high as 86% in
the last 1–2 weeks of life [2], and 20% of cancer deaths
attributable to cachexia [3]. Patients suffering cachexia may lose
up to 30% of their original body weight, with 45% of patients
losing more than 10% of their original weight over disease
progression [4].
Oxidative stress may play an integral role in cancer cachexia,
with evidence of oxidative damage and high levels of reactive
oxygen species (ROS) found in many cancer states [5]. The role of
ROS in the development of cancer cachexia, and the mechanisms
that cause the disease remain largely unknown, despite several
advances in identifying circulatory factors and pathways that are
active. A shift in the balance between reactive oxidants and
antioxidants can induce a state of oxidative stress that is
detrimental to the cell, and may be one of the key factors in the
development of cachexia.
Superoxide dismutase (SOD) is an enzyme responsible for the
dismutation of superoxide anion (O2
2?) into hydrogen peroxide
and oxygen. The activity of SOD has been shown to be decreased
in the cachectic state [6,7], indicating that there is an inability to
compensate for increases in ROS, and therefore an inability to
protect the cell from oxidative stress in the cachectic state. The
antioxidant enzymes catalase and Glutathione Peroxidase (GPx)
that break down hydrogen peroxide into oxygen and water have
also been found to have lower activity in cancer cachexia studies
[8], indicating that the systems could be key contributors to
oxidative stress and damage observed in cancer cachexia.
Whilst some of the pathways involved in the excess production
of ROS have been studied at length in cancer cachexia, there are
others that have been shown to play a role in oxidative insult in
other diseases, which have yet to be studied in detail in cancer
cachexia. Xanthine oxidoreductase is an enzyme with two distinct
forms that are responsible for catalyzing the conversion of
hypoxanthine to xanthine, and xanthine to uric acid [9]. Xanthine
Dehydrogenase (XDH) is expressed in vivo, and uses NAD+ as an
electron acceptor for the reduction reaction, forming NADH. In
the presence of pro-inflammatory mediators, XDH readily cleaves
into Xanthine Oxidase (XO), which instead uses molecular oxygen
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for the conversion of hypoxanthine to xanthine, and xanthine to
uric acid, producing the highly reactive O2
2?, or hydrogen
peroxide [9].
Whilst XO is not usually present at high levels in skeletal
muscle, raised levels are commonly seen in muscle tissue damage
and ischemia-reperfusion injury [10]. High levels of XO have also
been observed in the blood of some cancer patients compared to
patients without cancer [11], and it is been suggested that
cachectic animals respond favorably when treated with XO
inhibitors [12]. The abundance of pro-inflammatory factors
present in cachexia may lead to an increase in the cleavage of
XDH to the XO form, explaining higher circulating levels of XO.
Increased levels of XO would then lead to the excess production of
ROS, and contribute to oxidative stress in cancer cachexia.
Oxypurinol is a noncompetitive, irreversible inhibitor of XO,
considered more potent than allopurinol, of which it is a
metabolite [10]. Currently oxypurinol is used as a treatment for
conditions in which XO is a contributor, and has been shown to
decrease tissue wasting and increase cardiac function in cachectic
animals [12,13]. A decrease in purine production and associated
metabolism requirements may prompt the reduction of XDH
expression, and therefore downstream activity of this enzyme. Uric
acid, produced by XO, increases the conversion of arachidonic
acid into its biologically active metabolites [14]. This in turn
increases the activation of NADPH Oxidase, perpetuating the
signaling cascade that results in the activation of increased
transcription of the components of the ubiquitin-proteasome
system.
The progressive catabolism of muscle in cancer cachexia
suggests a pivotal role in systems of protein degradation, such as
the ubiquitin proteolytic pathway (UPP). The UPP has been found
to be up-regulated both in experimental models and patients with
cachexia [15,16], indicating contribution to muscle loss and
associated negative outcomes. Before proteins are degraded by the
UPP, they must be targeted by conjugated to multiple molecules of
ubiquitin. In order for this conjugation to occur, ubiquitin must
first be activated by an ubiquitin-activating enzyme (E1), and then
transferred to the active site of an ubiquitin carrier protein (E2).
The bound E2 recognizes ubiquitin conjugating enzymes (E3 or
E3 protein ligase), which allow conjugation reactions to take place,
which form a chain of ubiquitins linked to each other and the
protein substrate. Only when ubiquitin is targeted to a selected
protein can it then be recognized by the proteasome, and
processed into smaller peptides [17]. Several E3 protein ligases
have been shown to be active during proteolysis in muscle atrophy,
in particular muscle-specific F-box (MAFbx)/atrogin-1 and muscle
specific ring finger 1 (MURF-1) [18].
Eicosapentaenoic acid (EPA) is a naturally occurring omega-3
fatty acid, found in oily fish and certain algae, widely considered to
have great potential as an antigenotoxic, antioxidant and
chemopreventive agent. Administration of EPA has been shown
to increase the activity of the ROS scavenging SOD [19], slow the
development of some cancers, and increase weight gain and
quality of life in pancreatic cancer patients [20]. In recent years,
EPA has been trialed as a treatment for cancer cachexia due to its
various roles as an agonist of SOD and in upstream regulation of
the expression and activity of the UPP [20–22]. EPA replaces
arachidonic acid in phospholipid membranes when consumed at
high levels [23], and has also been shown to inhibit 15-HETE
production from arachidonic acid, which has been implicated in
UPP regulation in murine models of cachexia [24,25]. Some
animal trials of EPA have been successful, as has its combination
with other therapeutic approaches in human patients, such as
leucine supplementation, high protein diet and exercise [26,27].
The current study aimed to establish whether inhibition of
xanthine oxidase by oxypurinol had a beneficial effect in treatment
of muscle wasting in cancer cachexia. Further, the researchers
sought to ascertain whether EPA in combination with oxypurinol
Figure 1. Tumor growth. Data presented as mean 6 SEM.
doi:10.1371/journal.pone.0045900.g001
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Figure 2. Weight-loss over time. Data presented as mean 6 SEM.
doi:10.1371/journal.pone.0045900.g002
Figure 3. Wet muscle weights as percentage of final body weight. Data presented as mean 6 SEM. a significantly different compared to
control, b significantly different compared to EPA, c significantly different compared to oxypurinol (P,0.05).
doi:10.1371/journal.pone.0045900.g003
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was an effective multimodal treatment for muscle wasting in
cancer cachexia. It was hypothesized that the inhibitory effect of
oxypurinol on XO combined with the agonistic effect of EPA on
SOD would reduce the presence of excess O2
2?in cachectic
muscle, leading to a reduction in oxidative insult and resultant
injury or wasting when compared with cachectic controls.
Results
Animal Model
Four animals from the control group and one each from the
oxypurinol and combination treatment groups were culled prior to
the conclusion of the trial due to ethical concerns, and were not
included in statistical analyses.
Mice in the control group showed tumor onset from 660.3 days
(Figure 1), whilst the age and weight matched EPA (1060.7 days)
and oxypurinol (960.6 days) treatment groups had a significant
delay in tumor onset by comparison (P,0.001). The EPA group
also had significantly delayed onset compared to the combination
group (760.7 days, P,0.001). The oxypurinol treatment delayed
tumor onset compared to the combination (P,0.01) group. There
was no statistical difference in size of final tumor between EPA
(338667 mm3) and control (308628 mm3) groups, while oxypur-
inol (489678 mm3) and combination (515641 mm3) treatment
groups showed increased final tumor size compared to both
control (P,0.01) and EPA groups (P,0.05).
Weight-loss was calculated as a percentage of initial weight,
corrected for tumor mass (Figure 2). The control group
experienced significant weight-loss compared to initial weight
from day 12 onward (P,0.05). The EPA group increased in body
weight during the pre-cachectic phase, before weight stabilization,
and maintained this pre-cachectic state until day 22, when weights
started to decline, with significant weight-loss from day 25. The
oxypurinol group experienced gradual decline from peak weight
from day 3, before a sharp decrease in weight at day 13. Weight
loss was significant in this group from day 14 and gradually
decreased to endpoint. The combination group recovered from a
sharp decline in body weight at day 4, significantly increasing in
body weight from initial, and were stable before experiencing
significant weight-loss from day 17 (excluding day 19; P,0.01).
The control group had average weight change of 29.06% at
euthanasia, the EPA group 24.91%, oxypurinol 29.11% and the
combination group 25.03%, There was no significant differences
in percentage weight-loss between groups at euthanasia. The EPA
treatment group displayed weight-loss significantly lower than the
control group (P,0.05) for an extended duration (Days 3–15, 17–
23, total 20 days) compared to both the oxypurinol (Days 3, 4, 7,
8, 10, total 5 days) and combination (Days 6–12, 19, total 8 days)
treatment groups. Whilst there was a very strong correlation
between tumor size and weight loss in the control group (r2 = 0.94),
less variation was explained by the correlation between weight loss
and tumor size in the EPA (r2 = 0.72), oxypurinol (r2 = 0.72), and
combination (r2 = 0.70) treatment groups.
In the EPA treatment group, quadriceps, soleus, TA and
gastrocnemius muscles constituted a significantly higher percent-
age of total body weight than the control group at end point
(P#0.05; Figure 3). In the oxypurinol treatment group, TA and
gastrocnemius were also a significantly higher percentage of total
body weight compared to the control group at end point (P#0.05).
Weights of soleus, TA and gastrocnemius were also greater than
the control group in animals subjected to the combination
treatment (P#0.05). Quadricep weight increased in the EPA
treatment group compared to both oxypurinol and combination
treatments, however TA and plantarus were also decreased
compared to oxypurinol and combination groups, respectively.
Oxidative Stress
8-OH-dG levels in gastrocnemius muscle from the control
group was 12.961.4 pg/ml. EPA (18.263.2 pg/ml) and combi-
nation (18.463.7 pg/ml) groups had significantly higher levels
than the control group (P#0.05; Figure 4), indicating increased
oxidative stress in these groups. The oxypurinol group did not
display significantly higher 8-OH-dG levels compared to control
(14.961.5 pg/ml, P#0.07).
Gene Expression
Gene expression in gastrocnemius muscle is shown in Table 1.
The antioxidant component GPx1 increased 3.1-fold in the EPA
group and 4.1-fold in the oxypurinol group compared to control
(P,0.01), as did the expression of the ubiquitin E3-ligases MURF1
and MAFbx, .2.5-fold in the EPA group, and 2.8-fold and 3.6-
fold in the oxypurinol group respectively (P,0.05). Oxypurinol
also increased expression of antioxidant components MnSOD by
Figure 4. Gastrocnemius 8-OH-dG levels as a marker of
oxidative stress. Data presented as mean 6 SEM. a significantly
different compared to control, b significantly different compared to EPA,
c significantly different compared to oxypurinol (P,0.05).
doi:10.1371/journal.pone.0045900.g004
Table 1. Gene expression in gastrocnemius muscle.
Gene EPA Oxypurinol Combination
CuZnSOD 0.9060.1 1.2860.2 0.8060.1c
MnSOD 1.6960.1 1.8660.25a 0.9360.2c
EcSOD 1.3660.3 1.0260.1 0.2960.3abc
GPx1 3.0860.3a 4.1460.3a 1.3860.3bc
CAT 1.8060.4 2.3960.2ab 0.5860.2c
XDH 1.0260.5 2.6960.3ab 0.6660.3c
NOX2 1.0360.2 0.6160.2 0.5360.2b
MAFbx 2.5160.4a 3.5660.3a 0.6560.2bc
MURF-1 3.2160.3a 2.7660.4a 0.5160.2bc
UbB 1.1760.3 1.3060.2a 0.7360.2c
Data presented as fold change relative to control. a significantly different
compared to control, b significantly different compared to EPA, c significantly
different compared to oxypurinol (P,0.05).
doi:10.1371/journal.pone.0045900.t001
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1.9-fold (P,0.05) and CAT by 2.4-fold (P,0.01) compared to
control, while XDH increased 2.7-fold (P,0.01) and a 1.3-fold
increase in proteasome subunit UbB (P,0.05) was observed. The
treatments in combination decrease EcSOD expression 0.3-fold
compared to control values (P,0.05).
Figure 5. Enzyme activity in gastrocnemius tissue. Data presented as mean6 SEM. a significantly different compared to control, b significantly
different compared to EPA, c significantly different compared to oxypurinol (P,0.05).
doi:10.1371/journal.pone.0045900.g005
Table 2. PCR primers for gene expression.
Forward Reverse
CuZnSOD 59-TGAACCAGTTGTGTTGTCAG-39 59-TCCATCACTGGTCACTAGCC-39
EcSOD 59-AGGTGGATGCTGCCGAGAT-39 59-TCCAGACTGAAATAGGCCTCAAG-39
MnSOD 59-TGGCTTGGCTTCAATAAGGA-39 59-AAGGTAGTAAGCGTGCTCCCACAC-39
CAT 59-CGGCACATGAATGGCTATGGATC-39 59-CGGCACATGAATGGCTATGGATC-39
GPx1 59-GGGCTCCCTGCGGGGCAAGGT-39 59-ATGTACTTGGGGTCGGTCATG-39
XDH 59-ATCTGGAGACCCACTGCACC-39 59-TGTGCTCACGAAGAGCTCCAT-39
NOX2 59-TTGGGTCAGCACTGGCTCTG-39 59-TGGCGGTGTGCAGTGCTATC-39
Ubiquitinb 59-GCTCAGTGACGAGAGGCTTT-39 59-TCACGAAGATCTGCATTTTGA-39
MAFbx 59-AAGATCAAACGCTTGCGAAT-39 59-GAACATCATGCAGAGGCTGA-39
MURF1 59-AGGAGCAAGTAGGCACCTCA-39 59-GTCCATGTCTGGAGGTCGTT-39
doi:10.1371/journal.pone.0045900.t002
EPA and Oxypurinol Treatment of Cancer Cachexia
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Enzyme Assays
Activity of total SOD significantly increased in the oxypurinol
group (32.261.5 U/ml; Figure 5) compared to control (27.061.3
U/ml, P,0.01), combination (25.063.4 U/ml, P,0.01) and EPA
groups (28.361.5 U/ml, P,0.05). There was no change between
other groups. Activity of GPx was significantly reduced in the EPA
group (8.7662.0 U/ml) compared to both the control
(14.061.9 U/ml, P,0.05) and combination groups
(13.662.0 U/ml, P,0.05). Catalase activity was reduced in the
combination group (14.462.8 U/ml) compared to both the
control (20.962.0 U/ml, P,0.01) and oxypurinol groups
(24.364.7 U/ml, P,0.05). There were no other significant
changes between groups. There was no significant difference in
XO activity between groups.
Discussion
EPA has been generally accepted to have the potential to assist
in the treatment of cancer cachexia, in particular as part of a
combined approach to therapy [26,27], however further elucida-
tion of the exact mechanisms is required. In the current study,
animals treated with EPA had significantly delayed tumor
development, and therefore improved outcomes, which may have
been due to EPA’s previously described anti-tumor action [28],
rather than anti-cachectic action alone. However, while inhibited
tumor growth may partially explain attenuation of weight loss,
previous research indicates that the anti-cachectic effect of EPA is
larger than would be expected given the magnitude of tumor
reduction [29], and appears to elicit a response distinct from the
anti-tumor effect [30], supporting the view that the increased
variation seen in the EPA group in this study may be due to factors
other than inhibited tumor growth. Future studies would benefit
from the animals being culled at weight-loss or tumor size limits,
rather than arbitrary dates, in order to establish if animals treated
with EPA experience similar weight-loss to untreated animals with
similar tumor size and mass, despite delayed onset.
Long chain n-3 PUFA, such as EPA, are known to be
compromised by oxidative stress, forming lipid hydroperoxidases
and fatty acid peroxyl radicals which in turn may damage lipid
membranes [31]. The incorporation of EPA into lipid membranes
of cells in animals undergoing supplementation [23] may increase
the susceptibility of these membranes to oxidative damage,
including cell and nuclear membranes, and further exposing cell
contents including DNA, to the increased oxidative state, and may
explain the increased oxidative damage to DNA indicated by the
levels of 8-OH-dG in the EPA group. 8-OH-dG is the
predominant form of free radical-induced oxidative lesion, and is
commonly used as biomarker for oxidative stress [32]. 8-OH-dG is
produced during oxidative damage to DNA, caused by interaction
between the hydroxyl radical and nucleotide bases of DNA
strands, and is considered a well characterized and sensitive
marker of such damage [32].
EPA treatment caused a decrease in GPx activity compared to
the control group at end point. This decrease in antioxidant
capacity may also be indicative of a decreased requirement for
antioxidant action, due to either reduced ROS presence or
increased ROS scavenging by other enzymes. There was also no
change in SOD or catalase activity. Together, this indicates that
EPA’s action is not as an agonist of antioxidant activity as
hypothesized, and that by end point, the potential for increased
antioxidant action indicated by the increase in GPx1 gene
expression is being dampened in this group. Thus despite changes
in gene expression that in the absence of disease may have caused
increased activity of antioxidant enzymes such as GPx, the
presence of cancer cachexia prevented such functional changes
from occurring. By completion of the study, the EPA group had
begun to decline in weight, and it is therefore possible that an
earlier effect of EPA on antioxidant function caused the delayed
onset of weight-loss; however further time-course studies are
required to confirm this hypothesis. The decline in body weight in
the EPA group at the end of the study was indicative of cancer
cachexia being present.
A previous study has indicated that inhibition of XO by
oxypurinol treatment reduced loss of total body weight and lean
body mass, and reduced the production of ROS compared to
controls [12]. However, the current study suggests that oxypurinol
treatment may cause adverse outcomes in the rodent model, in
particular the rapid decline of performance indicated by weight-
loss seen early in disease. Up-regulation of components of the UPP
also suggests a shift toward muscle wasting in this group. Indeed,
oxypurinol, rather than decreasing the activity of XO, caused no
overall change when compared to the control group. When seen in
context of the increased gene expression of XDH, this indicates
that there may be an inhibitory effect, which is being compensated
for by increased production of XOR. The oxypurinol treatment
group also exhibited a trend toward increased oxidative damage
compared to control (,0.07) indicating there may be an increased
abundance of ROS. Increased activity of SOD in this group
compared to control shows increased scavenging of ROS, most
likely in response to this increase in oxidative damage. These
differences in response may be due to a low bioavailability of
oxypurinol in the method of administration used in this study [13],
and alternative, higher potency preparations or modes of delivery
should be considered in future studies. Future studies into the role
of XOR and purine metabolism in cachexia may also benefit from
inhibition of this pathway at a point upstream of XOR. However,
due to differences between rodent and primate metabolism of
purines, it is important that this pathway be investigated fully in a
model that allows clinical parallels to be drawn.
During study progression, the combination group displayed
weight-loss phase characteristics similar to both the EPA and
oxypurinol groups. For example, the initial weight increase and
stabilization reflects the EPA group, the sharp decline at 12 days
mirrors that of the oxypurinol group at 14 days. The amount of
weight lost by the combination group is, for the most part, not as
extreme as the oxypurinol group, but weight is not as well
preserved as the EPA group. These weight-loss patterns are also
distinct from the control group, indicating that it is the
combination of the two groups, rather than a lack of effect,
causing this pattern of decline. An interaction between the two
treatments is further supported by gene expression and enzyme
activity data, where the effect in the combination group is
significantly different from the effect of either treatment alone.
Given the significant changes in many parameters experienced
in the combination therapy group compared to either component
in isolation, it is possible that the pathways altered by EPA and
oxypurinol are linked. Although EPA has been previously shown
to suppress urate crystal-induced inflammation in Sprague-Dawley
rats [33], this has not previously been shown in a model of
cachexia. Further research is required, but the intersection of these
two pathways at arachidonic acid is the most likely point of
interaction [14,23,24]. The combined inhibition of the UPP by
EPA and oxypurinol is supported by the reduction in gene
expression of UbB, MURF1, and MAFbx in this study (See
Table 1). Inhibited action of the pathway upstream of NADPH
Oxidase by EPA and oxypurinol is further supported by the trend
toward a decrease in expression of NOX2 in the combination
treatment group compared to control (P,0.06), and the decreased
EPA and Oxypurinol Treatment of Cancer Cachexia
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expression of NOX2 in the combination group compared to the
EPA group indicates that the compound effect of the combination
therapy is increasing inhibition of this pathway, most likely via the
previously proposed mechanism. A decrease in purine production
and associated metabolism requirements, triggered by feedback
inhibition of amidophosphoribosyl transferase [13], may prompt
the reduction of XDH expression seen in the combination group.
The significant changes seen in the combination group may also
be caused by increased uptake of oxypurinol due to altered
permeability of cell membranes caused by EPA supplementation,
and may be the cause of the apparent interaction. Altered fluidity
and phospholipid composition of cell membranes has been
observed following n-3 PUFA supplementation [34], modifying
the uptake of hydrophobic drugs. Given the relatively high lipid
solubility of oxypurinol [13], this alteration would allow the drug
to pass easily via passive diffusion.
Conclusion
EPA continues to show promise as part of a multi-modal
treatment for cachexia, with a positive shift towards maintenance
of lean muscle mass, and delayed onset of weight-loss in animals
undergoing EPA treatment compared to those receiving other
treatments. Mechanisms of protection were no longer active at
end-point studied, therefore time-course studies are required to
determine those responsible for the protective effects observed.
Oxypurinol appears to cause an increased rate of weight decline in
mice with cancer cachexia compared to all other treatment
groups. This indicates that XO may play a protective role during
the progression of cancer cachexia, and its inhibition is detrimental
to outcomes. However, preservation of mass in certain muscles
implies that oxypurinol may be beneficial in maintaining muscle
mass. The increased effects in the combination group compared to
the EPA or oxypurinol treatments suggest an intersection of the
two mechanistic pathways, or that there in an increased uptake of
oxypurinol in the presence of EPA supplementation, causing the
apparent interaction. Further investigations are required to fully
elucidate the interactive effect of oxypurinol and EPA, and the role
of XO in cancer cachexia.
Materials and Methods
Cell Culture
The murine adenocarcinoma 16 (MAC16) cell line was cultured
in RPMI with 10% FBS and 0.5% penicillin/streptomycin
(Invitrogen, Mulgrave, Australia). Cells were grown to 80%
confluence, centrifuged at 500 g for 5 minutes at 4uC, and isolated
from the growth media. Cells were then resuspended in sterile
PBS, and drawn into a 25-gauge needle for injection.
Animal Model
All animal experiments carried out in this study were approved
by the Animal Welfare Committee, at Deakin University (approval
number A13/2010). Female Balb/c nu nu mice aged 8 weeks
(Animal Resource Centre, Canning Vale, Australia) were housed
in groups of 5, with free access to standard chow and water
throughout the study, weighed weekly to determine consumption.
Ambient temperature was controlled at 22uC62uC, at 40–60%
humidity, with a 12-hour light/dark cycle. Mice were injected with
previously prepared cells, then randomized into 4 groups,
consisting of EPA treatment (EPAX, Aalesund, Norway, 0.4 g/
kg/day, n= 9 [EPA]), oxypurinol treatment (Sigma-Aldritch,
Castle-Hill, Australia; 1 mmol/L in drinking water, n = 9),
combination treatment (as per EPA and oxypurinol groups
n= 9), or the cancer cachexia control group (n = 13). Animals
were monitored daily for changes in body weight, and tumor sizes
measured using calipers. Mice were terminated by sodium
pentobarbital injection (30 mg/kg) (Virbac Animal Health,
Regents Park, Australia) at 29 days, when weight loss reached
25%, or tumor size reached 1000 mm3, whichever occurred first.
Muscle tissues, including gastrocnemius, soleus, plantarus, tibialis
anterior (TA), and quadriceps, were removed and weighed. All
samples were snap frozen and stored at 280oC for further
analysis.
Oxidative Stress
An ELISA kit was used to measure the DNA oxidation
byproduct 8-hydroxy-2-deoxy guanosine (8-OH-2dG) (StressMarq
Biosciences, Victoria, Canada) as a marker of oxidative stress [32].
DNA was extracted from 10 mg of gastrocnemius muscle using a
DNA isolation kit (Promega, Sydney, Australia). Each sample was
then diluted so that 50 mg of DNA was used in the 8-OH-2dG
assay. The competitive immunoassay involves the binding of free
8-OH-2dG to an antibody coated 96 well plate. The assay and
sample concentration of 8-OH-2dG were carried out as per the
manufacturer’s instructions.
Gene Expression
Total RNA was extracted from 10 mg of frozen gastrocnemius
muscle using TRI reagent (Astral Scientific, Sydney, Australia)
according to the manufacturer’s specification. The total RNA
concentration was determined by A260/A280 measurement. One
microgram of total RNA was reverse transcribed into cDNA using
AMV reverse transcriptase first strand cDNA synthesis kit
according to the manufacturer’s protocol (Marligen Biosciences,
Sydney, Australia). Real-Time PCR was performed using a Bio-
Rad IQ5 detection system, with reactions performed using SYBR
Green Supermix (Bio-Rad, Sydney, Australia). Primers were
designed using Primer 3, and obtained from GeneWorks
(Hindmarsh, Australia; See Table 2). The amplification of cDNA
samples was carried out using IQ SYBR greenTM following the
manufacturers protocols (BioRad, Sydney, Australia) Fluorescent
emission data was captured and mRNA levels were analyzed using
the critical threshold (CT) value [35]. Thermal cycling and
fluorescence detection were conducted using the BioRad IQ5
sequence detection system (BioRad, Sydney, Australia). Samples
were normalized for the cDNA concentration determined with
OliGreen (Invitrogen, Mulgrave, Australia) [36].
Protein & Enzyme Activity Analysis
Gastrocnemius muscle tissue samples (20 mg) were homoge-
nized and centrifuged at 10,000 g at 4uC for 10 minutes. The
protein concentration was determined via the Bradford method
(BioRad, Sydney, Australia). Total SOD, glutathione peroxidase
(GPx), catalase, and XO activity were measured with commercial
enzyme assay kits as per the manufacturer’s instructions (Sapphire
Bioscience, Waterloo, Australia; Invitrogen, Mulgrave, Australia).
Statistics
All statistical analyses were performed using SPSS Statistics
Version 17.0 (IBM, Chicago, USA) or GraphPad Prism 5
(GraphPad Software, San Diego, USA), with results expressed as
mean 6 standard error of mean (SEM) and considered statistically
significant if P,0.05, unless otherwise stated. Data was analyzed
using two-way ANOVA, with a Tukey’s test post hoc analysis
performed to determine differences between groups where
appropriate. Correlation was analysed using Pearsons Test
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Weight-loss data was analyzed using Repeated Measures ANOVA
with Bonferroni post-hoc analysis.
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